Results 31 to 40 of about 4,006,149 (207)
Frontiers in Immunology, 2021 Osteoarthritis (OA) is a serious joint inflammation that leads to cartilage degeneration and joint dysfunction. Mesenchymal stem cells (MSCs) are used as a cell-based therapy that showed promising results in promoting cartilage repair.
Murad Alahdal +8 more
doaj +1 more source
IDO Inhibition Facilitates Antitumor Immunity of Vγ9Vδ2 T Cells in Triple-Negative Breast Cancer
Frontiers in Oncology, 2021 Triple-negative breast cancer (TNBC) escape from immune-mediated destruction was associated with immunosuppressive responses that dampened the activation of tumor-infiltrating CD8 and γδ T cells.
Peng Li +15 more
doaj +1 more source
Evaluation of mode of indoleamine 2,3-dioxygenase 1 inhibition by 4,7-dichloroquinolines
European Journal of Medicinal Chemistry Reports, 2023 Herein, we report the development of synthetically simpler analogs of 4,7-dichloroquinoline (DCQ) as apo-indoleamine 2,3-dioxygenase 1(IDO1) protein targeting ligand to inhibit the activity of IDO1 enzyme.
Niku Moni Das +8 more
doaj +1 more source
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1)
, 2019 Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in the kynurenine pathway of tryptophan metabolism, which is involved in immunity, neuronal function, and aging.
Pierre Vogel (1856911) +5 more
core +4 more sources
Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors
Frontiers in Pharmacology, 2022 Erlotinib is a highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor for the targeted therapy of non-small-cell lung cancer (NSCLC) However, the efficacy of erlotinib is limited because the development of drug ...
Xi-xi Hou +6 more
doaj +1 more source
Frontiers in Immunology, 2021 Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance to checkpoint immunotherapies.
Yvonne Grobben +16 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Indoleamine 2,3-dioxygenase 1 (IDO1) plays a predominant role in cancer immunotherapy which catalyzes the initial and rate limiting steps of the kynurenine pathway as a key enzyme.
Gui-Qing Xu +9 more
doaj +1 more source
Frontiers in Chemistry, 2022 Among cancer cells, indoleamine 2, 3-dioxygenase1 (IDO1) activity has been implicated in improving the proliferation and growth of cancer cells and suppressing immune cell activity. IDO1 is also responsible for the catabolism of tryptophan to kynurenine.
Dong Kwon Kim +30 more
doaj +1 more source
Indoleamine 2,3-dioxygenase 1 inhibitor Epacadostat combined with IFN-γ induces apoptosis of triple-negative breast cancer cell lines [PDF]
Jichu yixue yu linchuang, 2020 Objective To investigate the effect of IFN-γ combined with IDO1 inhibitor Epacadostat(Epa) on the treatment of triple-negative breast cancer cell lines 4T1 and MDA-MB-231.
HU Qing-qing, LU Yan
doaj
Autoimmunity, 2021 Indoleamine 2,3-dioxygenase1(IDO1) is one of the most important proteins in protect the embryos from the mother's immune system during pregnancy. However, the regulation of the protein expression at the maternal–foetal interface is not fully known.
Minyan Yang +6 more
doaj +1 more source